iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference

Rhea-AI Summary

Insight Molecular Diagnostics (Nasdaq: IMDX) has scheduled its second quarter 2025 financial results release for August 11, 2025, after market close. The company will host a live Zoom webinar at 2:00 PM PT / 5:00 PM ET on the same day to discuss the results, followed by a Q&A session.

Additionally, CEO Josh Riggs and CFO Andrea James will participate in the 10th Annual Needham Virtual MedTech & Diagnostics Conference on August 12, 2025, where they will be available for one-on-one meetings with investors.

News Market Reaction – IMDX

-5.78%

1 alert

-5.78% News Effect

On the day this news was published, IMDX declined 5.78%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

NASHVILLE, Tenn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it will report second quarter 2025 financial results after the market closes on Monday, August 11, 2025. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day.

The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDX Q2 2025 Earnings Webinar.

An archived replay will be available after the call concludes on iMDX’s investor relations website at https://investors.imdxinc.com/.

10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

Separately, on August 12^th, Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 10th Annual Needham Virtual MedTech & Diagnostics Conference, taking place from August 11-12, 2025.

Investors wishing to book one-on-one meetings with management are encouraged to reach out to their Needham sales representative.

Event: 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
Dates: August 12, 2025
Location: Virtual

About Insight Molecular Diagnostics Inc. 

Insight Molecular Diagnostics Inc., or iMDx, formerly Oncocyte Corp. (OCX), is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes.

iMDx™, GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, and VitaGraft™ are trademarks of Insight Molecular Diagnostics Inc. 

Insight Molecular Diagnostics (Nasdaq: IMDX) moved its headquarters from Irvine, Calif., to Nashville, Tenn., in June 2025. The company’s new NASDAQ symbol became effective June 18. Investors may visit https://investors.imdxinc.com/ for more information.

Investor Contact: 

Doug Farrell 
LifeSci Advisors LLC 
dfarrell@lifesciadvisors.com

FAQ

When will IMDX release its Q2 2025 earnings?

IMDX will release its Q2 2025 earnings on August 11, 2025 after the market closes.

How can investors access IMDX's Q2 2025 earnings call?

Investors can access the earnings call via a live Zoom webinar at 2:00 PM PT / 5:00 PM ET on August 11, 2025. Registration is required, and a replay will be available on the company's investor relations website.

Who will represent IMDX at the Needham Virtual MedTech Conference?

CEO Josh Riggs and CFO Andrea James will represent IMDX at the conference.

How can investors schedule meetings with IMDX management at the Needham Conference?

Investors interested in one-on-one meetings should contact their Needham sales representative to schedule meetings for August 12, 2025.